Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP
Por:
Onida, F, Sbianchi, G, Radujkovic, A, Sockel, K, Kroger, N, Sierra, J, Socie, G, Cornelissen, J, Poire, X, Raida, L, Bourhis, JH, Finke, J, Passweg, J, Salmenniemi, U, Schouten, HC, Beguin, Y, Martin, S, Deconinck, E, Ganser, A, Zver, S, Lioure, B, Rohini, R, Koster, L, Hayden, P, Iacobelli, S, Robin, M, Yakoub-Agha, I
Publicada:
1 jun 2022
Ahead of Print:
1 mar 2022
Resumen:
Recently a new three-group clinical classification was reported by an International Consortium to stratify CMML patients with regard to prognosis. The groups were defined as follows: (1) Myelodysplastic (MD)-CMML: WBC <= 10 x 10(9)/l, circulating immature myeloid cells (IMC) = 0, no splenomegaly; (2) MD/MP (overlap)-CMML: WBC 10-20 x 10(9)/l or WBC <= 10 x 10(9)/l but IMC > 0 and/or splenomegaly; (3) Myeloproliferative (MP)-CMML: WBC > 20 x 10(9)/l. By analysing EBMT Registry patients who underwent allo-HCT for CMML between 1997 and 2016, we aimed to determine the impact of this classification on transplantation outcome and to make a comparison with the conventional WHO classification (CMML-0/CMML-1/CMML-2). Patient grouping was based on the data registered at time of transplantation, with IMC replaced by peripheral blasts. Among 151 patients included in the analysis, 38% were classified as MD-CMML, 42% as MD/MP-CMML and 20% as MP-CMML. With a median survival of 17 months in the whole series, MD-CMML patients were distinguished as a low-risk group with higher CR rate at transplant and a longer post-transplant 2-year progression-free survival in comparison to others (44.5% vs 33.5%, respectively), whereas the WHO classification was superior in identifying high-risk patients (CMML-2) with inferior survival outcomes.
Filiaciones:
Onida, F:
Univ Milan, Fdn IRCCS CaGranda Osped Maggiore Policlin, Milan, Italy
Sbianchi, G:
Tor Vergata Univ, Dept Biol, Rome, Italy
Radujkovic, A:
Heidelberg Univ, Heidelberg, Germany
Sockel, K:
Tech Univ Dresden, Univ Hosp Dresden, Dresden, Germany
Kroger, N:
Univ Hosp Eppendorf, Hamburg, Germany
Sierra, J:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Socie, G:
Hosp St Louis, Paris, France
Cornelissen, J:
Erasmus MC Canc Inst, Rotterdam, Netherlands
Poire, X:
Clin Univ St Luc, Brussels, Belgium
Raida, L:
Palacky Univ, Fac Hosp Olomouc, Dept Hematooncol, Olomouc, Czech Republic
Palacky Univ, Fac Med & Dent, Olomouc, Czech Republic
Bourhis, JH:
Gustave Roussy, Inst Cancerol, Villejuif, France
Finke, J:
Univ Freiburg, Freiburg, Germany
Passweg, J:
Univ Hosp, Basel, Switzerland
Salmenniemi, U:
Turku Univ Hosp, Turku, Finland
Schouten, HC:
Univ Hosp Maastricht, Maastricht, Netherlands
Beguin, Y:
CHU Liege, Liege, Belgium
Univ Liege, Liege, Belgium
Martin, S:
Robert Bosch Krankenhaus, Stuttgart, Germany
Deconinck, E:
Hosp Jean Minjoz, Besancon, France
Ganser, A:
Hannover Med Sch, Hannover, Germany
Zver, S:
Univ Med Ctr, Ljubljana, Slovenia
Lioure, B:
Nouvel Hop Civil, Strasbourg, France
Rohini, R:
Univ Nottingham, Nottingham, England
Koster, L:
EBMT Data Off Leiden, Leiden, Netherlands
Hayden, P:
Trinity Coll Dublin, St Jamess Hosp, Dept Haematol, Dublin 8, Ireland
Iacobelli, S:
Tor Vergata Univ, Dept Biol, Rome, Italy
Robin, M:
Hosp St Louis, Paris, France
Yakoub-Agha, I:
Univ Lille, CHU Lille, Infinite, INSERM U1286, F-59000 Lille, France
Green Published, Green
|